Sector News

AZ spends $200M to expand US biologics site

November 24, 2014
Life sciences
AstraZeneca has announced plans to expand its US biologics manufacturing centre in Frederick, Maryland, spending more than $200 million to increase production in support of its “maturing pipeline”.
 
The company says the investment will help it keep pace “with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline”. The expansion, which is expected to be complete in mid-2017, will add 40,000 square feet of manufacturing, laboratory and administrative space and bring 300 new jobs to the site; the company currently employs over 3,000 people in Maryland.
 
Andrew Skibo, regional head of biologics supply for AstraZeneca, noted that the firm’s MedImmune unit “has a robust pipeline of more than 120 biologics, including more than 30 in clinical development. The expansion of our Frederick facility will support the progression of drug candidates across our core therapeutic areas”.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”